NeuroSense schedules Nasdaq hearing for November amid listing issues

Tue, 13 Oct 2026 08:31:01 -0400

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced that its hearing before the Nasdaq Hearings Panel is scheduled for November 10, 2026, following its appeal of a Staff Delisting Determination issued October 1, 2026.

The appeal stays any suspension or delisting action, allowing the company's ordinary shares and warrants to continue trading on the Nasdaq Capital Market under the tickers "NRSN" and "NRSNW," respectively, pending the panel's decision.

The company said it has already regained compliance with Nasdaq's $1.00 minimum bid price requirement. The remaining deficiency is the $35 million minimum market value of listed securities requirement under Rule 5550(b)(2). At the hearing, NeuroSense

NeuroSense schedules Nasdaq hearing for November amid listing issues

Tue, 13 Oct 2026 08:31:01 -0400

NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones

Tue, 13 Oct 2026 08:30:00 -0400

Shares continue to trade on Nasdaq pending the Panel's decision; minimum bid price compliance already regained

Near-term catalysts include a New Drug Submission to Health Canada targeted for December 2026 and a decision on non-dilutive funding for the Phase 3 PARAGON trial expected in Q1 2027

NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones

Tue, 13 Oct 2026 08:30:00 -0400

Shares continue to trade on Nasdaq pending the Panel's decision; minimum bid price compliance already regained

Near-term catalysts include a New Drug Submission to Health Canada targeted for December 2026 and a decision on non-dilutive funding for the Phase 3 PARAGON trial expected in Q1 2027

NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones

Tue, 13 Oct 2026 08:30:00 -0400

Shares continue to trade on Nasdaq pending the Panel's decision; minimum bid price compliance already regained

Near-term catalysts include a New Drug Submission to Health Canada targeted for December 2026 and a decision on non-dilutive funding for the Phase 3 PARAGON trial expected in Q1 2027

NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones

Tue, 13 Oct 2026 08:30:00 -0400

Shares continue to trade on Nasdaq pending the Panel's decision; minimum bid price compliance already regained

Near-term catalysts include a New Drug Submission to Health Canada targeted for December 2026 and a decision on non-dilutive funding for the Phase 3 PARAGON trial expected in Q1 2027

NeuroSense faces Nasdaq delisting risk over market value rule

Fri, 02 Oct 2026 16:20:38 -0400

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced it received a Staff Determination from Nasdaq's Listing Qualifications Department on October 1, 2026, stating the company has not regained compliance with Nasdaq Listing Rule 5550(b)(2), which requires a minimum market value of listed securities (MVLS) of $35 million for continued listing on The Nasdaq Capital Market.

The company was first notified on April 2, 2026, that its MVLS had fallen below $35 million for 30 consecutive trading days. Under Nasdaq rules, NeuroSense was given 180 calendar days, until September 29, 2026, to regain compliance. Having failed to meet that deadline, Nasdaq determined that the

NeuroSense faces Nasdaq delisting risk over market value rule

Fri, 02 Oct 2026 16:20:38 -0400

NeuroSense faces Nasdaq delisting risk over market value rule

Fri, 02 Oct 2026 16:20:38 -0400

NeuroSense faces Nasdaq delisting risk over market value rule

Fri, 02 Oct 2026 16:20:38 -0400

NeuroSense Provides Update on Nasdaq Listing Compliance

Fri, 02 Oct 2026 16:15:00 -0400

Company regains compliance with Nasdaq's minimum bid price requirement and intends to request a Nasdaq Hearings Panel hearing to seek additional time to regain compliance with the minimum market value requirement

CAMBRIDGE, Mass., Oct. 2, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing

NeuroSense Provides Update on Nasdaq Listing Compliance

Fri, 02 Oct 2026 16:15:00 -0400

CAMBRIDGE, Mass., Oct. 2, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing

NeuroSense Provides Update on Nasdaq Listing Compliance

Fri, 02 Oct 2026 16:15:00 -0400

CAMBRIDGE, Mass., Oct. 2, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing

NeuroSense Provides Update on Nasdaq Listing Compliance

Fri, 02 Oct 2026 16:15:00 -0400

CAMBRIDGE, Mass., Oct. 2, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS